High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience

Clinical and Experimental Allergy

Volumn 44, Issue 1, 2014, Pages 121-129

  Gulen T ^a,b   Hagglund H ^a   Dahlen B ^a,b   Nilsson, G ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anaphylaxis; Atopic disease; Hymenoptera venom; IgE sensitization; Mastocytosis; Prevalence; Tryptase

Indexed keywords

HYMENOPTERA VENOM; METHACHOLINE;

ADULT; ANAPHYLAXIS; ANIMAL; ARTICLE; BONE MARROW; CONTROLLED STUDY; DANDER; DERMATOPHAGOIDES; DOG; FEMALE; GRASS; HUMAN; INSECT; INSECT STING; MAJOR CLINICAL STUDY; MALE; MAST CELL; MASTOCYTOSIS; NONHUMAN; POLLEN; PREVALENCE; PRIORITY JOURNAL; SENSITIZATION; SKIN TEST; SYSTEMIC MASTOCYTOSIS;

ANAPHYLAXIS; ATOPIC DISEASE; HYMENOPTERA VENOM; IGE SENSITIZATION; MASTOCYTOSIS; PREVALENCE; TRYPTASE;

ADULT; AGED; AGED, 80 AND OVER; ALLERGENS; ANAPHYLAXIS; COMORBIDITY; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PREVALENCE; RISK FACTORS; SKIN TESTS; YOUNG ADULT;

EID: 84890813890     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12225     Document Type: Article

References (37)

1. Sampson HA, Munoz-Furlong A, Campbell RL et al. Second symposium on the definition and management of anaphylaxis: summary report - second national institute of allergy and infectious disease/food allergy and anaphylaxis network symposium. J Allergy Clin Immunol 2006; 117:391-7.
2. Yocum MW, Butterfield JH, Klein JS et al. Epidemiology of anaphylaxis in Olmstead County: a population based study. J Allergy Clin Immunol 1999; 104:452-6.
3. Helbling A, Thomas H, Müller U, Pichler WJ. Incidence of anaphylaxis with circulatory symptoms. A study over a 3-year period comprising 940 000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy 2004; 34:285-90.
4. Bohlke K, Davis RL, DeStefano R et al. Epidemiology of anaphylaxis among children and adults enrolled in a health maintenance organization. J Allergy Clin Immunol 2004; 113:536-42.
5. Decker WW, Campbell RL, Manivannan V et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 2008; 122:1161-5.
6. Lieberman P, Camargo CA Jr, Bohlke K et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006; 97:596-602.
7. Valent P, Horny H-P, Escribano L et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603-25.
8. Valent P, Akin C, Escribano L et al. Standards and standardization in mastocytosis: consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria. Eur J Clin Invest 2007; 37:435-53.
9. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004; 55:419-32.
10. Horny HP, Akin C, Metcalfe DD et al. Mastocytosis (Mast cell disease). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW eds. World Health Organization (WHO) Classification of Tumours, Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues, vol 2. Lyon, France: IARC Press, 2008; 2:54-63.
11. Valent P, Akin C, Sperr WR et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122:695-717.
12. Escribano L, Alvarez-Twose I, Sanchez-Munoz L et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish network on mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124:514-21.
13. Lim KH, Tefferi A, Lasho TL et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113:5727-36.
14. Escribano L, Akin C, Castells M, Schwartz LB. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006; 5:61-77.
15. Florian S, Krauth MT, Simonitsch-Klupp I et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005; 136:273-80.
16. Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish Network on Mastocytosis (REMA). Clin Exp Allergy 2007; 37:1547-55.
17. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226-32.
18. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25:543-51.
19. Horny HP, Sillaber C, Menke D et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998; 22:1132-40.
20. Escribano L, Orfao A, Diaz-Agustin B et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998; 91:2731-6.
21. Sotlar K, Escribano L, Landt O et al. One-step detection of c-kit point mutations using PNA-mediated PCR-clamping and hybridization probes. Am J Pathol 2003; 162:737-46.
22. Position paper: allergen standardization and skin tests. The European Academy of Allergology and Clinical Immunology. Allergy 1993; 48(14 Suppl):48-82.
23. GINA Workshop Report. Global strategy of asthma management and prevention - updated April 2002 (Scientific information and recommendations for asthma programs. NIH Publication No. 02-3659), 2002.
24. Warm K, Backman H, Lindberg A, Lundbäck B, Rönmark E. Low incidence and high remission of allergic sensitization among adults. J Allergy Clin Immunol 2012; 129:136-42.
25. Norrman E, Rosenhall L, Nyström L, Jönsson E, Stjernberg N. Prevalence of positive skin prick tests, allergic asthma, and rhinoconjunctivitis in teenagers in northern Sweden. Allergy 1994; 49:808-15.
26. Lötvall J, Ekerljung L, Rönmark EP et al. West Sweden Asthma Study: prevalence trends over the last 18 years argues no recent increase in asthma. Respir Res 2009; 10:94.
27. Ditto AM, Harris KE, Krasnick J, Miller MA, Patterson R. Idiopathic anaphylaxis: a series of 335 cases. Ann Allergy Asthma Immunol 1996; 77:285-91.
28. Tejedor MA, Sastre J, Sánchez JJ, Pérez C, de la Hoz B. Idiopathic anaphylaxis: a descriptive study of 81 patients in Spain. Ann Allergy Asthma Immunol 2002; 88:313-8.
29. Georgitis J, Reisman R. Venom skin tests in insect-allergic and insect non-allergic populations. J Allergy Clin Immunol 1985; 76:803-7.
30. Golden DBK, Kagey-Sobotka A, Hamilton RG, Norman PS, Lichtenstein LM. Insect allergy with negative venom skin tests. J Allergy Clin Immunol 2001; 107:897-901.
31. Kranke B, Sturm G, Aberer W. Negative venom skin test results and mastocytosis. J Allergy Clin Immunol 2004; 113:180-1.
32. Bonadonna P, Zanotti R, Pagani M et al. How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy 2009; 64:1379-82.
33. Muller U, Helbling A, Hunziker T et al. Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa. Allergy 1990; 45:597-603.
34. van Anrooij B, van der Veer E, de Monchy JG et al. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol 2013; 132:125-30.
35. Alvarez-Twose I, Zanotti R, González-de-Olano D et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol 2013; pii: S0091-6749(13)00988-3. doi: 10.1016/j.jaci.2013.06.020 [Epub ahead of print].
36. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007; 119:1550-1.
37. Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O'Hehir RE. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 2010; 65:926-7.